Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Target Lowered at Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its target price cut by Royal Bank Of Canada to $1.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 123.71% from the company’s previous close.

Several other research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 27th. Cantor Fitzgerald lowered shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday, August 17th. Guggenheim lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday. Mizuho restated a “neutral” rating and set a $0.50 target price on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Finally, Weiss Ratings upgraded shares of Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $21.85.

Eyepoint Pharmaceuticals Trading Up 1.6%

Shares of EYPT opened at $0.45 on Tuesday. The firm’s 50-day moving average is $4.77 and its two-hundred day moving average is $10.30. Eyepoint Pharmaceuticals has a twelve month low of $0.40 and a twelve month high of $19.11. The firm has a market capitalization of $38.54 million, a P/E ratio of -0.12 and a beta of 1.67.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The company had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Analysts predict that Eyepoint Pharmaceuticals will post -3.51 EPS for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Commodore Capital LP purchased a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $36,414,000. Hsbc Holdings PLC purchased a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $10,743,000. Janus Henderson Group PLC raised its stake in shares of Eyepoint Pharmaceuticals by 22.6% in the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock valued at $46,419,000 after acquiring an additional 663,439 shares during the period. Stempoint Capital LP raised its stake in shares of Eyepoint Pharmaceuticals by 129.1% in the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after acquiring an additional 456,915 shares during the period. Finally, Walleye Capital LLC purchased a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at $3,869,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Some analysts see potential recovery value at the current price. Mizuho maintained its neutral rating while assigning a $0.50 price target, and Jefferies moved to hold with a $1.00 target. These targets imply substantial upside from the current $0.44 level, although both firms remain cautious. TickerReport analyst coverage
• Positive Sentiment: Unusual options activity included the purchase of 7,885 call contracts, about 69% above typical daily volume, suggesting some traders are positioning for a potential rebound. However, options activity is not confirmation of a fundamental recovery.
• Neutral Sentiment: HC Wainwright and Mizuho reaffirmed neutral ratings. Their stance indicates limited conviction that the remaining pipeline currently supports a bullish investment case.
• Negative Sentiment: JPMorgan downgraded EyePoint from neutral to underweight, while Guggenheim cut its rating from buy to neutral. The downgrades reflect reduced confidence after the LUCIA setback.
• Negative Sentiment: EyePoint is cutting 53% of its workforce and halting wet AMD clinical trials early after disappointing LUCIA results. The company is redirecting resources toward DURAVYU’s diabetic macular edema program, but the restructuring underscores the loss of a major development catalyst. Benzinga workforce and clinical-trial report
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses after the trial disclosure. The investigation adds legal and reputational risk. Levi and Korsinsky investigation notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.